ProImmune Videos – ProImmune

ProImmune Videos
Mastering Immunity 2018 Mastering Immunity Europe 2018 Mastering Immunity 6 (2017) Mastering Immunity Europe 2017 Mastering Immunity Europe 2016 Mastering Immunity 5 (2015) Mastering Immunogenicity 4 (2014) Mastering Immunogenicity 3 (2013) Mastering Immunogenicity 2 (2012) Best Practice Immunogenicity Risk Management (2012)
Mastering Immunity 2018

Dr. Marcus Butler UHN Toronto “Optimizing Adoptive T cell Therapies”	Dr. Marianne Stanford VP Research, IMV “De novo generation of tumor specific T cell responses utilizing a novel oncology driven delivery platform”	Dr. Emilee Knowlton ProImmune “Epitope identification and clinical immune monitoring in gene therapy and immune oncology program”

Dr. Priya Sriraman Celgene “Measuring Host-vs-CAR-T Immune Responses”	Dr. Zuben Sauna FDA “Use of the MHC Associated Peptide Proteomic (MAPPs) assay to understand clinical outcomes associated with the use of Factor VIII in the treatment of Hemophilia A”	Dr. Shahla Abdollahi Celgene “Mechanisms of Immune Modulation by the Gut Microbiome – Implications for Autoimmunity”

Dr. Amy Rosenberg FDA “So You Think You Have Mastered Immunity? Cautionary Tales from the Immunology Revolution”	Dr. Jeremy Fry ProImmune “An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”	Dr. Jochem Gokemeijer Bristol-Myers Squibb “Immunogenicity Risk Assessment Tool Box for Biologics Drug Development”

Dr. Sophie Tourdot Pfizer “Non-clinical immunogenicity risk assessment of therapeutic proteins”	Dr. Andrea Ferrante Lilly “In silico prediction of immunogenicity: filling the gaps”	Dr. Rodd Polsky GSK “Format and Interpretation of a Drug Tolerant Approach for Measuring Circulating Immune Complex and Free Anti-Drug Antibodies in Preclinical Studies”

Dr. Inderpal Singh Teva Pharmaceuticals “Immunogenicity risk assessment of process-related impurities”	Dr. Jad Maamary Merck & Co. “In Silico and In Vitro Tools to Investigate Increased Immunogenicity Incidence Observed in Combination Therapies”
Mastering Immunity Europe 2018

Dr. Lotta Jansson Apitope “Apitopes to induce immune tolerance – mechanism and action”	Dr. Aileen Rowan Imperial College, London “Turnover and transformation of T cell clones in retroviral infection and leukaemia”	Prof. Paul Brenchley University of Manchester “Identifying T & B Cell autoantigen epitopes in Autoimmune Membranous Nephropathy”

Dr. Margot El-Khouri ProImmune “Epitope identification and clinical immune monitoring in immune oncology programs”	Dr. Yongliang Zhang National University Singapore “DUSP10 in inflammation and cancer”	Dr. Guy Hermans Isogenica “Using synthetic antibody libraries to overcome poor immunogenicity”

Dr. Katie Ewer University of Oxford “Potent cellular and humoral immunogenicity of a pre-erythrocytic viral vectored malaria vaccine in African infants and children”	Dr. Ilaria Esposito University of Oxford “Induction of specific CD4+ T cell helper responses following recombinant ChAd3/MVA vaccination against HCV”	Dr. Isabelle Turbica Université Paris-Sud “Impact of protein aggregates from biopharmaceuticals on dendritic cells”

Dr. Eleni Chantzoura Agenus “Mammalian Display for TCR discovery & Phosphopeptide neoantigens as targets”	Dr. Jeremy Fry ProImmune “An Integrated Approach to Managing Immunogenicity Risk and Optimum Protein Design”	Dr. Joleen White EMD Serono “Low Immunogenicity of Avelumab, An Immune Checkpoint Inhibitor Demonstrating Antitumor Activity”

Dr. Richard Sainson Kymab “Long-term in vivo anti-tumour efficacy of KY1044 (anti-ICOS) as monotherapy and in combination with anti-PD-L1”	Dr. Stephen Man Cardiff University School of Medicine “CD8+ T cell recognition of unusual and unnatural peptide epitopes”	Prof. Beatriz Carreno University of Pennsylvania “Personalized Cancer Vaccines”

Prof. Fiona Powrie University of Oxford “Host microbe interactions in the intestine: New therapeutic strategies in IBD”
Mastering Immunity 6 (2017)

Dr. Valerie Quarmby Genentech “Host Cell Proteins and Immunogenicity”	Dr. Daron Forman Bristol-Myers Squibb “The use of immunogenicity risk assessment tools for lead optimization of biologics”	Dr. Erik Meyer GlaxoSmithKline “Therapeutic Immunogenicity: Target Interference and Cut Point Evaluation”

Dr. Jeremy Fry ProImmune “An integrated approach to managing immunogenicity risk and drug immune modulation”	Dr. Wojciech Jankowski FDA “Non-clinical Assessments of Immunogenicity”	Dr. Eric Zanelli Déclion Holdings “DP-C016, a phosphoTau vaccine for the treatment of tauopathies”

Dr. Nik Schwabe ProImmune “Epitope identification and clinical immune monitoring in immune oncology programmes”	Mr Govinda Sharma British Columbia Cancer Agency “Functional identification of CD8+ T cell epitopes by parallel interrogation of more than a million distinct peptide-coding sequences”	Dr. Scott McClain Syngenta Crop Protection “Bioinformatic screen and detection of immunologically relevant cross-reactive IgE-binding epitopes”
Mastering Immunity Europe 2017

Dr. Bernard Maillère CEA, France “Specificity and phenotype of pre-existing T cells against therapeutic proteins”	Dr. Menna Clatworthy University of Cambridge, UK “Immune complexes modulate immune highways and DC trafficking”	Prof. Farzin Farzaneh King’s College London, UK “Therapeutic Cancer Vaccines”

Dr. Bartek Zuber Swedish Orphan Biovitrum, Sweden “Immunogenicity assessment for Affibody-Fc fusion therapeutics “	Dr. Tim Hickling Pfizer, USA “Applying in vitro immunogenicity assays to predicts clinical immunogenicity“	Dr. Sophie Sibéril UPMC, Paris, France “Analysis of peripheral T cell compartments in high-grade Follicular Lymphoma patients treated with rituximab-based regimens”

Prof. Yu-Chan Chao Academia Sinica, Taiwan “Display of foreign surface antigens on baculovirus as pseudotyped viruses for immunological studies and applications”	Prof. Tim Elliott University of Southampton, UK “Applying mechanism based computational models to CTL epitope prediction”	Prof. Mark Exley Agenus Inc., USA “Phosphopeptide NeoAntigens for Tumor Immunity: Novel therapeutic options”

Prof. Christine Falk Medizinische Hochschule Hannover, Germany“Precision Medicine in Transplantation – immune monitoring for the discrimination of GVHD, rejection and CMV infection”	Prof. Miles Carroll Public Health England, UK “Understanding the immune response to EBOV during acute disease and in EVD survivors”
Mastering Immunity Europe 2016

Prof. Herman Waldmann University of Oxford “Short-term therapeutic intervention for the therapeutic harnessing of tolerance mechanisms”	Dr. Farnaz Fallah-Arani UCB Pharma, UK “Challenges to experimental design to test immunotherapeutic drugs to achieve clinically relevant results.”	Dr. Jeremy Fry ProImmune Ltd., UK “An integrated approach to managing immunogenicity risk and drug immune modulation.”

Dr. Bernd Schlereth Covagen, Switzerland “Special considerations in pharmacokinetic and immunogenicity assessment of bispecific antibody constructs”	Dr. Bernard Maillère CEA, France “Comprehensive analysis of pre-existing T cells specific to therapeutic proteins in healthy donors”	Prof. David Wraith University of Bristol “Antigen-specific tolerance induction: allergy, autoimmunity and anti-drug antibodies”

Dr. Peter Adler Wurtzen ALK-Abelló, Denmark “Immunological biomarkers in Allergy Immunotherapy”	Prof. Paul Moss University of Birmingham “Direct visualisation of antigen-specific CD4+ T cells: insights from HLA class II tetramers”	Prof. Ada Kruisbeek DCPrime, The Netherlands “Developing off-the-shelf dendritic cell based vaccines: pre-clinical and clinical observations”

Dr. Wei Xue Roche Innovation Center Zurich, Switzerland “Combination immunotherapy and vaccines in cancer”
Mastering Immunity 5 (2015)

Dr. Ethan Shevach NIAID, NIH “Tregs -ready for the clinic”	Dr. Keith Knutson Mayo Clinic, Jacksonville “Vaccines for Prevention of Breast Cancer”	Prof. Jean Rommelaere DKFZ, Germany “Use of oncolytic parvoviruses in the treatment of malignant gliomas: a viro-immunotherapeutic approach”

Dr. Jeremy Fry ProImmune “An integrated approach to managing immunogenicity risk and drug immune modulation”	Dr. Xiaoying Chen Pfizer, Inc. “A Systems Pharmacology Approach to Immunogenicity – A multi-scale, Mechanistic Mathematical Model and Its Applications”	Prof. Armagan Kocer University of Groningen “Ion channel decorated liposomes: therapeutic potential and immunogenicity”

Prof. David Wraith University of Bristol “Switching off immunity: the mechanism of antigen-specific immunotherapy”	Prof. Julio Delgado University of Utah “Assessment of TNF-alpha antagonists and Anti-Drug Antibodies in the Clinical Laboratory”	Dr. Gene Olinger NIAID, NIH “Development of a monoclonal antibody cocktail for Ebola virus therapy: convergence of plants, mice, and humans”

Prof. Lawrence Steinman Stanford University “Vaccines, adjuvants, and autoimmunity”

Mastering Immunogenicity 4 (2014)

Prof. Herman Waldmann University of Oxford “Tolerance can be induced in the adult immune system”	Prof. Arlene Sharpe Harvard University “T Cell Coinhibitory Pathways and Cancer Immunotherapy: Roles of the PD-1 pathway in controlling tolerance and tumor immunity”	Dr. Timothy Hickling Pfizer, Inc. “Contribution of ex vivo assays to immunogenicity risk assessment”

Dr. Sabine Zollner CSL Behring “Preclinical characteristics of rVIII-SingleChain, a novel recombinant single-chain FVIII under clinical development at CSL Behring”	Dr. Nades Palaniya The Hospital for Sick Children, Toronto “Targeting innate immune collectins and neutrophil extracellular traps (NETs) to regulate inflammatory diseases”	Dr. Joleen White Biogen IDEC “Evaluation of Peginterferon Beta-1a and Interferon Beta-1a Pharmacokinetics, Pharmacodynamics, and Immunogenicity in Multiple Sclerosis”

Dr. Jeremy Fry ProImmune “Tools and Technologies for Immunogenicity Risk Management”	Dr. Bruce Hall University of New South Wales “Antigen specific CD4+CD25+Foxp3+Treg generated from natural Treg (nTreg)”	Dr. Amy Loercher GSK “ABIRISK Developments and Challenges: Perspectives from Year 2”

Dr. Susan Kirshner FDA “Therapeutic Proteins: Routes of Exposure and the risk of immunogenicity”

Mastering Immunogenicity 3 (2013)

Prof. David Wraith University of Bristol “Dealing with Unwanted Immunogenicity: The Design and Development of Tolerogenic T Cell Epitopes”	Dr. Florian Deisenhammer Innsbruck “Drug Immunogenicity: Lessons Learnt from Interferon-beta”	Dr. Beth Chang Amunix “XTEN in Blood Factor Engineering”

Dr. William Sanderson University College London “Phenotypic Structure of B Cell Subsets as a Tool for the Investigation for Immunogenicity”	Dr. Michael Cancro University of Pennsylvania “B Cell Selection and Survival: First Order Consideration for Immunogenicity”	Dr. Larry Kauver Trellis “Antibody Repertoire Monitoring: Application to Anti-Drug Antibodies”

Dr. Jeremy Fry ProImmune “Mastering Immunogenicity: Tools and Technologies”	Dr. Samuel Pine Allergan “Immunologic Endpoints for Guiding Biologic Drug Development”	Dr. Caroline Barelle University of Aberdeen “Shark VNAR Domains: Immunogenicity Determination in the Early Stages of Development Aids Candidate Selection for “First-Man” Studies”

Dr. Federico Mingozzi University Pierre et Marie Curie “Assessing and Modulating Immune Responses to AVV Vectors in Humans”

Mastering Immunogenicity 2 (2012)

Dr. Manoj Rajadhyaksha Regeneron “Working towards building a “Value Added Proposition” for Immunogenicity Prediction and Risk Management”	Dr. Bonnie Rup Pfizer “Understanding the problem of unwanted immunogenicity risk in biotherapeutic discovery and development: advances, gaps, opportunities”	Dr. Jeremy Fry ProImmune “Tools and technologies for comprehensive immunogenicity risk management”

Dr. Nikolai Schwabe ProImmune “Mastering Immunity: ProStorm™ Cytokine Release Assay”	Dr. Bob DuBridge Full Spectrum Genetics “MapEng™ A Powerful, New Tool in the Engineering of Biobetter Therapeutics”

Best Practice Immunogenicity Risk Management (2012)

Dr. Tim Hickling Pfizer “Immunogenicity of biotherapeutics: Why do we care and where do we stand?”	Dr. Robin Thorpe NIBSC Health Protection Agency “CHMP Guidance on Unwanted Immunogencity: Best Practice Iummunogenicity Risk Management: Oxford 2012”	Dr. Katharina Steinitz Baxter Innovations GmbH “Identification of promiscuous FVIII-specific CD4+ T-cell epitopes in a humanized mouse model for hemophilia A”

Dr. Heather Hinton Roche “Pre-Clinical Risk Assesment Using Innovative Technologies”	Dr. David Ulaeto DSTL “Therapeutic potential of a humanised antibody for the treatment of Venezuelan Equine Encephalitis Virus”